Gonadorelin FDA Approved Historical

What It Is

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). GnRH is a 10-amino-acid peptide (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) produced by neurons of the preoptic area of the hypothalamus. It is the master signal of the reproductive endocrine axis — released in discrete pulses into the hypothalamic-pituitary portal vasculature, it travels to the anterior pituitary, where it binds the GnRH receptor (GnRHR) on gonadotroph cells to trigger synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH in turn act at the gonads to drive gametogenesis, steroidogenesis, and ovulation.

GnRH was isolated and structurally characterized in 1971 by Andrew Schally and Roger Guillemin (working independently). The isolation required processing hundreds of thousands of animal hypothalami to yield enough peptide for sequencing — one of the most arduous biochemistry projects of the 20th century, and one for which Schally and Guillemin shared the 1977 Nobel Prize in Physiology or Medicine. The synthetic peptide was subsequently manufactured and made available as a pharmaceutical.

In the United States, gonadorelin has had multiple historical FDA approvals. Factrel (gonadorelin hydrochloride, Wyeth Ayerst) was approved as a single-dose diagnostic agent for assessing pituitary gonadotroph function; it was later discontinued commercially. Lutrepulse / Lutrelef (gonadorelin acetate, Ferring) was approved as a pulsatile infusion-pump drug for induction of puberty and ovulation in hypogonadotropic hypogonadism; it too has been discontinued in the U.S. market. Modern U.S. clinical use of gonadorelin — predominantly as an adjunct to testosterone replacement therapy (TRT) for fertility preservation — is almost entirely through 503A compounding pharmacies on off-label prescription.

The modern community surge in gonadorelin use was driven by regulatory circumstance rather than by superior clinical evidence. In 2020, the FDA reclassified human chorionic gonadotropin (HCG) as a biologic, which removed it from 503A compounding pharmacy access under the updated rules. HCG had been the standard TRT adjunct for preserving testicular size, intratesticular testosterone production, and spermatogenesis — but with HCG no longer compoundable, telehealth TRT clinics and men's-health practitioners adopted gonadorelin as a substitute. Gonadorelin acts one step upstream of HCG — at the pituitary rather than the testicle — which raises legitimate clinical questions about whether intermittent SubQ gonadorelin reliably overcomes the pituitary suppression induced by exogenous testosterone. The answer is generally "yes, sometimes — but less reliably than HCG."

Mechanism of Action

• GnRH receptor (GnRHR) agonism at the anterior pituitary — Gonadorelin binds GnRHR on pituitary gonadotroph cells, a Gq-coupled G-protein-coupled receptor. Activation triggers IP3 / DAG-mediated calcium release, PKC activation, and downstream synthesis and release of LH and FSH. This is the central pharmacological action.
• LH → testosterone cascade — LH travels via peripheral circulation to testicular Leydig cells, binding the LH / CG receptor (LHCGR) to drive intratesticular testosterone production. Intratesticular testosterone concentrations are 50–100x higher than circulating testosterone and are essential for spermatogenesis — which is why maintaining the LH signal on TRT matters even when circulating testosterone is supplied exogenously.
• FSH → spermatogenesis — FSH stimulates Sertoli cells in the seminiferous tubules to support spermatogenesis. FSH preservation is particularly critical for men who want to maintain fertility while on TRT.
• Continuous vs pulsatile paradox (the central mechanism) — GnRH pharmacology is inseparable from pulsatility. The pituitary gonadotroph requires intermittent GnRH pulses (typically every 60–120 minutes in healthy men) to maintain LH / FSH secretion. Continuous GnRH exposure causes rapid GnRH receptor downregulation and desensitization — which paradoxically suppresses rather than stimulates LH / FSH output. This is the mechanism behind the GnRH-agonist prostate cancer drugs (leuprolide, goserelin, triptorelin): chronic continuous exposure suppresses the axis. Belchetz 1978 (Science, PMID 100651) is the foundational paper demonstrating this paradox in rhesus monkeys; Hoffman & Crowley 1982 (NEJM, PMID 6811941) showed pulsatile GnRH induces puberty in hypogonadotropic men.
• Short half-life aligns with pulsatile pharmacology — Gonadorelin's ~2–10 minute plasma half-life means each injection creates a brief, discrete pulse that clears rapidly — aligned with the natural pulsatile pattern rather than mimicking continuous exposure. This pharmacologic advantage is the reason gonadorelin (and not a long-acting GnRH analog) is appropriate for stimulating rather than suppressing the axis.
• Practical translation for TRT — Twice-daily SubQ gonadorelin in TRT protocols generates 2 discrete pulses per day versus the ~12–16 natural pulses a healthy hypothalamus generates. Whether 2 pulses daily is sufficient to reliably maintain pituitary responsiveness during TRT-induced suppression is an open and practically important question. Some patients respond; some do not; testicular volume and LH / FSH labs are the practical read-out.

What the Research Shows

• Foundational pharmacology — continuous vs pulsatile (Belchetz 1978, PMID 100651) — Belchetz PE et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978;202(4368):631-633. Demonstrated in ovariectomized rhesus monkeys that pulsatile GnRH maintains LH / FSH output while continuous GnRH paradoxically suppresses it. The foundational paper for the entire GnRH pharmacology.
• Puberty induction in hypogonadotropic men (Hoffman & Crowley 1982, PMID 6811941) — Hoffman AR, Crowley WF. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 1982;307(20):1237-1241. Pulsatile SubQ GnRH restored LH / FSH, testosterone, and spermatogenesis in men with isolated hypogonadotropic hypogonadism.
• Diagnostic efficacy — Gonadorelin is well-established as a diagnostic tool for assessing pituitary function. A single 100 mcg IV or SubQ injection reliably produces an LH / FSH surge in individuals with intact pituitary function, confirming gonadotroph response capacity. The former FDA indication for Factrel.
• Pulsatile pump protocols for hypogonadotropic hypogonadism — In reproductive endocrinology, pulsatile GnRH infusion via pump (every 60–120 minutes at 5–25 mcg per pulse) reliably restores LH / FSH secretion, testosterone production, and spermatogenesis in men and ovulation in women. The strongest evidence base for gonadorelin. Lutrepulse / Lutrelef was the historical FDA-approved product for this indication.
• Limited data for TRT adjunct use (Kohn 2021, PMID 33705811) — Kohn TP et al. Effects of subcutaneous gonadotropin-releasing hormone administration on serum hormonal concentrations, semen parameters, and sperm retrieval in men with hypogonadism undergoing testosterone therapy. Urology 2021;153:148-153. Small series examining SubQ gonadorelin adjunct to TRT. Results were mixed — not all patients maintained spermatogenesis, and the study size is modest.
• HCG comparison — HCG directly mimics LH at the testicular level and has decades of clinical evidence for maintaining testicular function on TRT. Gonadorelin works upstream at the pituitary level, which is already suppressed by exogenous testosterone. This raises legitimate questions about whether intermittent SubQ gonadorelin can reliably overcome TRT-induced HPG suppression. No head-to-head RCT.
• Fertility preservation debate — Some reproductive endocrinologists question whether intermittent SubQ gonadorelin (without a pulsatile pump) provides sufficient and consistent enough stimulation to preserve spermatogenesis during TRT. Clinical evidence is significantly weaker than for HCG. For men with fertility as a primary goal, HCG (where accessible) or a reproductive endocrinologist-supervised pulsatile pump remains the more evidence-backed approach.

Human Data

Human data for gonadorelin span decades of clinical use in endocrinology, with the strongest evidence for diagnostic and pulsatile-pump applications and thinner evidence for the modern TRT adjunct role.

• Pulsatile GnRH for hypogonadotropic hypogonadism — Hoffman & Crowley 1982 (NEJM) and extensive subsequent literature demonstrate pulsatile SubQ gonadorelin via pump (every 60–120 minutes) reliably induces puberty, restores spermatogenesis, and produces fertility in men with isolated hypogonadotropic hypogonadism. Reproductive endocrinology standard of care for this rare indication. Response rates in published series approach 80–90% for testosterone normalization and 60–80% for spermatogenesis.
• Pulsatile GnRH for ovulation induction — Pulsatile gonadorelin was used for ovulation induction in women with hypothalamic amenorrhea — the original indication for Lutrepulse / Lutrelef. Largely displaced by recombinant gonadotropins in modern ART practice, but still used in some reproductive centers.
• Diagnostic testing (Factrel historical indication) — Single-dose gonadorelin is used to diagnose pituitary vs hypothalamic causes of hypogonadism. LH / FSH measured at baseline, 15, 30, and 60 minutes after 100 mcg SubQ or IV. Intact gonadotroph response confirms pituitary function.
• Kohn 2021 TRT series (PMID 33705811) — Small series examining SubQ gonadorelin adjunct to testosterone therapy in men. Mixed serum-hormone and semen-parameter outcomes. Underpowered for definitive conclusions.
• Telehealth TRT real-world experience (post-2020) — Since the 2020 HCG reclassification, hundreds of thousands of TRT patients have been prescribed compounded gonadorelin (typically 100–200 mcg SubQ 2x daily) as an HCG alternative. Real-world experience is favorable for most patients on testicular-volume preservation, less reliable for sperm-parameter preservation. Systematic outcomes data remains limited.
• Pediatric hypogonadism — Long-term pulsatile-pump gonadorelin has been used in adolescents with hypogonadotropic hypogonadism for puberty induction, with good safety and efficacy in specialty centers.

Dosing from the Literature

Reconstitution & Storage

Compounded gonadorelin is typically supplied as a lyophilized powder in multi-dose vials at 1 mg, 2 mg, 3 mg, or 5 mg, with BAC water supplied separately by the compounding pharmacy.

• Reconstitution — Inject bacteriostatic water slowly down the inside wall of the vial at 45°. Swirl gently — never shake. Solution should be clear and colorless.
• Storage — Lyophilized vial stable at 2–8°C refrigerated; some compounded formulations allow room-temperature storage short-term per manufacturer instructions. Reconstituted solution: 2–8°C, use within 28 days. Do not freeze reconstituted.
• Injection technique — 29G–31G insulin syringe; SubQ at 45° into abdomen or thigh; rotate sites. Very small volume (10 units = 0.1 mL at typical 1,000 mcg/mL concentration).
• Timing — Morning and evening doses for 2x daily protocols — roughly 12 hours apart. Not dependent on meals (unlike growth-hormone-secretagogue protocols).
• Inspection — Discard if cloudy, particulate, or discolored.

→ Use the Kalios Dosing Calculator for exact syringe units

Side Effects & Risks

• Injection-site reactions — Mild redness or irritation at the injection site. Generally well-tolerated.
• Headache — Occasionally reported. Usually mild and transient.
• Flushing — Transient facial warmth after injection. More common with higher doses.
• Nausea — Uncommon at standard doses.
• Hypersensitivity reactions — Rare anaphylactoid reactions have been reported historically with parenteral GnRH. Initial injection should ideally be under clinical supervision in sensitive patients.
• Pituitary desensitization (the key pharmacologic risk) — If injections are too frequent or delivered too close together (effectively approximating continuous exposure), the pituitary GnRH receptor can downregulate, paradoxically suppressing LH / FSH. Maintaining discrete pulsatile dosing (>4 hours apart; 2x daily is standard) is essential to avoid this.
• Insufficient efficacy — The most practically important "risk" is that the 2x-daily protocol may not adequately prevent testicular atrophy or maintain spermatogenesis during TRT, particularly if the pituitary is heavily suppressed. Monitor testicular volume, LH, FSH, and (if fertility matters) sperm parameters.
• Drug interactions — Concomitant androgen therapy (TRT) suppresses pituitary responsiveness; dose adjustments and monitoring are required. Concomitant GnRH-agonist drugs (leuprolide, goserelin) would be antagonistic.
• Pregnancy / lactation — Not routinely indicated in these contexts; the compound has ovulation-induction uses, which is a specialty-endocrinology application requiring close monitoring.
• WADA status — banned (males) — Gonadorelin is on the 2026 WADA Prohibited List under S2.2 (LH-releasing peptides and GnRH analogs, prohibited in males). Tested male athletes should not use.
• Sourcing — Compounded gonadorelin from 503A pharmacies is the legitimate U.S. supply. Research-chemical channel quality varies; independent COA (HPLC + mass spec) is the floor for non-pharmacy sourcing.

Bloodwork & Monitoring

• LH and FSH — Primary efficacy markers. If LH and FSH remain undetectable during TRT + gonadorelin, the protocol is not overcoming pituitary suppression. Check at baseline and at 4–8 weeks; repeat at 3 months.
• Total and free testosterone — Track as part of overall TRT monitoring. Gonadorelin does not directly drive serum testosterone (which is supplied by exogenous TRT); it is a marker of testicular function preservation via intratesticular testosterone.
• Estradiol — Monitor as part of TRT protocol. Intratesticular testosterone production contributes to local aromatization and circulating estradiol.
• Semen analysis — If fertility preservation is the goal, periodic semen analysis (sperm count, motility, morphology) is the only definitive measure of whether spermatogenesis is being maintained. Baseline before TRT, then at 3, 6, and 12 months if possible.
• Testicular volume — Clinical assessment of testicular size by provider (orchidometer) or self-exam. Volume decline indicates insufficient testicular stimulation.
• Inhibin B — A marker of Sertoli-cell function and spermatogenesis. Provides indirect evidence of maintained testicular function without a full semen analysis. Useful adjunct when semen analysis is logistically difficult.
• Prolactin — Baseline; elevated prolactin can independently suppress GnRH and should be addressed before attributing non-response to gonadorelin dosing.
• General TRT labs (CBC, CMP, hematocrit, PSA, lipid panel) — Per standard TRT monitoring cadence; not specific to gonadorelin.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Practical User Notes

• Work with a clinician who measures LH, FSH, and testicular volume — The standard "100 mcg 2x daily" default dose is not universally sufficient to overcome TRT-induced pituitary suppression. Measured LH / FSH response on labs is the correct feedback signal.
• Empty response on LH / FSH means the protocol is not working — If LH and FSH remain undetectable at 8 weeks on gonadorelin, the protocol is not overcoming TRT suppression. Options: increase frequency (3x daily), consider HCG where accessible, or consult a reproductive endocrinologist about pulsatile pump therapy.
• Injection timing — roughly 12 hours apart — Morning and evening doses for 2x daily protocols. Not dose-sensitive to meals.
• Short half-life is a feature, not a bug — Each SubQ injection creates a discrete ~2–10 minute plasma pulse, aligning with the natural pulsatile pattern. This is why gonadorelin (and not a long-acting GnRH analog) is used for stimulating rather than suppressing the axis.
• Do not combine with a GnRH agonist — Long-acting GnRH agonists (leuprolide, goserelin, triptorelin) produce chronic receptor exposure and paradoxical suppression. Gonadorelin would be pharmacologically antagonized.
• Fertility timing — Sperm parameters can take months to normalize on any protocol. If fertility is time-sensitive (e.g., planning conception within a year), semen banking before starting TRT is the highest-leverage intervention.
• Injection technique — 29G–31G insulin syringe; SubQ 45° into abdomen or thigh; rotate sites. Very small injection volume (10 units / 0.1 mL at typical 1,000 mcg/mL concentration).
• Reconstitute with bacteriostatic water — Compounding pharmacies typically supply BAC water with the vial. Store reconstituted at 2–8°C; use within 28 days.
• Testicular-volume self-monitoring — Orchidometer self-assessment or periodic clinician check. Testicular-volume decline is a lagging indicator of inadequate protocol.
• Allergic reactions — rare but real — Initial injection ideally under clinical supervision. Rare anaphylactoid reactions have been reported historically.
• Tested male athletes — do not use — WADA S2.2 prohibition in males. Detection methods established.
• Discontinuation — No taper required. Stopping gonadorelin while remaining on TRT returns the patient to baseline TRT-induced HPG suppression.

Regulatory Status

Related Compounds

People researching Gonadorelin often also look at these:

Next Steps

Key References

1. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631-633. PMID: 100651. (Foundational continuous-vs-pulsatile pharmacology paper.)
2. Hoffman AR, Crowley WF. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982;307(20):1237-1241. PMID: 6811941. (Pivotal pulsatile GnRH clinical paper.)
3. Schally AV, Arimura A, Baba Y, Nair RM, Matsuo H, Redding TW, Debeljuk L. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971;43(2):393-399. PMID: 4930263. (Schally GnRH isolation paper — Nobel Prize 1977.)
4. Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971;43(6):1334-1339. PMID: 4936338. (GnRH primary structure.)
5. Kohn TP, Louis MR, Pickett SM, Lindgren MC, Kohn JR, Pastuszak AW, Lipshultz LI. Effects of subcutaneous gonadotropin-releasing hormone administration on serum hormonal concentrations, semen parameters, and sperm retrieval in men with hypogonadism undergoing testosterone therapy. Urology. 2021;153:148-153. PMID: 33705811. (Modern TRT adjunct series.)
6. Santoro N, Filicori M, Crowley WF. Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. Endocr Rev. 1986;7(1):11-23. PMID: 3082643. (Pulsatile GnRH therapy review.)
7. Crowley WF, McArthur JW. Simulation of the normal menstrual cycle in Kallman's syndrome by pulsatile administration of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 1980;51(1):173-175. PMID: 6247353.
8. FDA. Factrel (gonadorelin hydrochloride) Prescribing Information. FDA.gov. Wyeth Ayerst (discontinued). (Historical FDA approval reference.)
9. FDA. Lutrepulse / Lutrelef (gonadorelin acetate) Prescribing Information. FDA.gov. Ferring (discontinued). (Historical FDA pulsatile-pump approval.)
10. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391-405. PMID: 8198392. (Comprehensive GnRH pharmacology review.)
11. Filicori M, Flamigni C, Dellai P, Cognigni G, Michelacci L, Arnone R, Sambataro M, Falbo A. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab. 1994;79(4):1215-1220. PMID: 7962300.
12. Seminara SB, Hayes FJ, Crowley WF Jr. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. Endocr Rev. 1998;19(5):521-539. PMID: 9793755.
13. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002;87(9):4128-4136. PMID: 12213860.
14. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271-1279. PMID: 24636400. (Context for modern HPG preservation strategies.)
15. Ramasamy R, Armstrong JM, Lipshultz LI. Preserving fertility in the hypogonadal patient: an update. Asian J Androl. 2015;17(2):197-200. PMID: 25337841. (TRT fertility preservation review — HCG context.)
16. WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (Gonadorelin banned in males under S2.2.)